Haemonetics Stock In The News
| HAE Stock | USD 77.41 0.23 0.30% |
Our overall analysis of Haemonetics' news coverage and content from conventional and social sources shows investors' bearish mood towards Haemonetics. The specific impact of Haemonetics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Haemonetics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Haemonetics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Haemonetics Backtesting and Haemonetics Hype Analysis. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
Haemonetics |
Haemonetics Today Top News and Investor Outlook
Haemonetics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Haemonetics and other traded companies coverage with news coverage. We help investors stay connected with Haemonetics headlines for the 25th of December to make an informed investment decision based on correlating the impacts of news items on Haemonetics Stock performance. Please note that trading solely based on the Haemonetics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Haemonetics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Haemonetics earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Haemonetics that are available to investors today. That information is available publicly through Haemonetics media outlets and privately through word of mouth or via Haemonetics internal channels. However, regardless of the origin, that massive amount of Haemonetics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Haemonetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Haemonetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Haemonetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Haemonetics alpha.
Haemonetics Largest EPS Surprises
Earnings surprises can significantly impact Haemonetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2003-07-24 | 2003-06-30 | 0.1 | 0.11 | 0.01 | 10 | ||
1999-10-28 | 1999-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
1999-01-29 | 1998-12-31 | 0.1 | 0.09 | -0.01 | 10 | ||
2004-07-29 | 2004-06-30 | 0.17 | 0.19 | 0.02 | 11 | ||
2004-05-03 | 2004-03-31 | 0.17 | 0.19 | 0.02 | 11 | ||
2004-01-22 | 2003-12-31 | 0.17 | 0.19 | 0.02 | 11 |
Haemonetics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Haemonetics Stock. Current markets are strongly bullish. About 82% of major world exchanges and indexes are currently up. See today's market update for more information.
24th of December 2024
Heres Why You Should Add HAE Stock to Your Portfolio Now at zacks.com
20th of December 2024
Investors three-year returns in Haemonetics have not grown faster than the companys underl... at finance.yahoo.com
18th of December 2024
ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker at zacks.com
17th of December 2024
SNN Stock Might Rise Following FDA Nod for AETOS Stemless at finance.yahoo.com
13th of December 2024
Blood Market to Grow by USD 2.6 Billion , Report on AI-Driven Market Transformation and Gr... at finance.yahoo.com
11th of December 2024
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-S... at businesswire.com
9th of December 2024
Should You Continue to Retain Insulet Stock in Your Portfolio Now at zacks.com
6th of December 2024
Barrington Research Reaffirms Outperform Rating for Haemonetics at thelincolnianonline.com
5th of December 2024
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios at finance.yahoo.com
2nd of December 2024
Should You Continue to Retain Bio-Techne Stock in Your Portfolio at zacks.com
14th of November 2024
Haemonetics to close California facility, lay off 75 people at finance.yahoo.com
7th of November 2024
Haemonetics earnings beat by 0.05, revenue topped estimates at investing.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Haemonetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Haemonetics' short interest history, or implied volatility extrapolated from Haemonetics options trading.
Check out Haemonetics Backtesting and Haemonetics Hype Analysis. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.375 | Earnings Share 2.41 | Revenue Per Share 26.77 | Quarterly Revenue Growth 0.086 | Return On Assets 0.0588 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.